Leal Therapeutics
Develops neuro-metabolic therapeutics for schizophrenia and ALS
$30MSeries A
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Develops neuro-metabolic therapeutics for schizophrenia and ALS
Develops oral small molecule therapies for immunological and chronic diseases
Develops next-generation therapies for migraine prevention
Develops ultrasound-mediated nonviral genetic medicines
Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies
Uses quantum chemistry and AI to design novel drug molecules
Provides AI-powered platforms and integrated services for drug discovery and development
Develops AI-driven drug discovery platform for first- and best-in-class therapeutics
Develops precision immunoregulatory medicines based on tissue Treg biology
Develops AI-driven drug discovery for proximity therapeutics